Therapeutic area intelligence for Neuromuscular Blocker with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

FDA →

STERISCIENCE →

Recent signals(2)

RegulatoryJuly 18, 2026

FDA Accepts Supplement Application for Rocuronium Bromide by Fresenius Kabi

The FDA has accepted a supplemental application for Rocuronium Bromide submitted by Fresenius Kabi.

StrategyJune 23, 2026

FDA Grants AP Status for Succinylcholine Chloride ANDA217873

The FDA has granted approval status (AP) for ANDA217873, a generic formulation of Succinylcholine Chloride by STERISCIENCE.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.